Dapagliflozin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Heart Failure With Reduced Ejection Fraction (HFrEF)
Conditions
Heart Failure With Reduced Ejection Fraction (HFrEF)
Trial Timeline
Apr 9, 2019 → Mar 7, 2020
NCT ID
NCT03877237About Dapagliflozin
Dapagliflozin is a phase 3 stage product being developed by AstraZeneca for Heart Failure With Reduced Ejection Fraction (HFrEF). The current trial status is completed. This product is registered under clinical trial identifier NCT03877237. Target conditions include Heart Failure With Reduced Ejection Fraction (HFrEF).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06610526 | Approved | Active |
| NCT05250011 | Pre-clinical | Completed |
| NCT03877237 | Phase 3 | Completed |
| NCT03877224 | Phase 3 | Completed |
| NCT03782259 | Approved | Completed |
| NCT03338855 | Approved | Completed |
| NCT03152084 | Approved | Terminated |
| NCT02585804 | Approved | Completed |
| NCT02460978 | Phase 3 | Completed |
| NCT02420392 | Pre-clinical | Completed |
| NCT01294436 | Phase 3 | Completed |
| NCT01165268 | Phase 1 | Completed |
| NCT01055652 | Phase 1 | Completed |
| NCT00908271 | Phase 1 | Completed |
| NCT00726505 | Phase 1 | Terminated |
| NCT00554450 | Phase 1 | Completed |
Competing Products
20 competing products in Heart Failure With Reduced Ejection Fraction (HFrEF)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IV diuretic | Nuwellis | Pre-clinical | 15 |
| IV Loop Diuretics | Nuwellis | Pre-clinical | 15 |
| Stepped pharmacologic care | Nuwellis | Phase 3 | 69 |
| IV Loop Diuretics (LD) | Nuwellis | Pre-clinical | 15 |
| TRV120027 + Normal Saline | Trevena | Phase 1 | 25 |
| TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo | Trevena | Phase 2 | 44 |
| TRV120027 + Placebo | Trevena | Phase 1/2 | 33 |
| Ilofotase alfa + Placebo | AM-Pharma | Phase 2 | 44 |
| INXN-4001 | Precigen | Phase 1 | 28 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 33 |
| SGLT2i, beta blocker, ARNI, MRA, MTD | Eli Lilly | Approved | 85 |
| Pactimibe, CS-505 | Daiichi Sankyo | Phase 2 | 52 |
| Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeks | Daiichi Sankyo | Approved | 85 |
| olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetil | Daiichi Sankyo | Phase 3 | 77 |
| Olmesartan | Daiichi Sankyo | Phase 3 | 77 |
| Carperitide + Placebo | Daiichi Sankyo | Phase 2 | 52 |
| Edoxaban | Daiichi Sankyo | Pre-clinical | 23 |
| Regadenoson | Astellas Pharma | Phase 1 | 33 |
| Advagraf + Prograf | Astellas Pharma | Phase 2 | 52 |
| FK506E | Astellas Pharma | Phase 3 | 77 |